Amylyx Pharmaceuticals, INC 8-K filings

Amylyx Pharmaceuticals reported Q2 2026 financial results, highlighting the completion of patient visits for the pivotal Phase 3 LUCIDITY trial of avexitide, with topline data expected in late August or early September 2026.

Amylyx Pharmaceuticals stockholders approved director elections, ratified auditor appointment, and advisory compensation at the June 4, 2026 Annual Meeting.

Amylyx Pharmaceuticals reported Q1 2026 financial results, highlighting progress in its Phase 3 LUCIDITY trial for avexitide with topline data anticipated in Q3 2026 and a cash runway extending into 2028.

Amylyx Pharmaceuticals updated its corporate presentation, highlighting completed enrollments in Phase 3 LUCIDITY and Phase 1 LUMINA trials, alongside positive Phase 2 HELIOS data.

Amylyx Pharmaceuticals announced its fourth quarter and full year 2025 financial results, highlighting reduced net losses and progress in its pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia.

Amylyx Pharmaceuticals announced the selection of AMX0318 as a development candidate for post-bariatric hypoglycemia and other rare diseases, alongside updates on its robust neurodegenerative and endocrine pipeline.

Amylyx Pharmaceuticals reported Q3 2025 financial results, updated on its pivotal Phase 3 LUCIDITY trial for avexitide, and extended its cash runway into 2028.

Amylyx Pharmaceuticals, Inc. entered into an underwriting agreement to sell 17.5 million shares of common stock, aiming to raise approximately $164.0 million in net proceeds.

Amylyx Pharmaceuticals announced the discontinuation of its AMX0035 program for progressive supranuclear palsy (PSP) following a Phase 2b trial that showed no efficacy.

Amylyx Pharmaceuticals reported second quarter 2025 financial results, highlighting progress in its clinical pipeline including anticipated Phase 3 data for avexitide and FDA Fast Track designation for AMX0114.

Amylyx Pharmaceuticals, Inc. announced the results of its Annual Meeting of Stockholders held on June 5, 2025, where all three proposals, including the election of Class I directors, ratification of the independent auditor, and an advisory vote on executive compensation, were approved.

Amylyx Pharmaceuticals announced its Q1 2025 financial results, highlighting progress in clinical trials for avexitide, AMX0035, and AMX0114, and reporting a cash runway through the end of 2026.

Amylyx Pharmaceuticals reports its Q4 and full year 2024 financial results, highlighting progress in its pipeline, including the Phase 3 LUCIDITY trial for avexitide and a recent public offering to extend cash runway.

Amylyx Pharmaceuticals has entered into an underwriting agreement to sell 17,142,857 shares of common stock at $3.50 per share, potentially raising $65.5 million if the underwriter's option is fully exercised.

Amylyx Pharmaceuticals has partnered with Gubra A/S to develop a long-acting GLP-1 receptor antagonist, with potential milestone payments and royalties for Gubra.

Amylyx Pharmaceuticals announced its third quarter 2024 financial results, highlighted by progress in clinical trials and a strategic acquisition, while also reporting a net loss.

Amylyx Pharmaceuticals reported positive topline data from its Phase 2 HELIOS trial, showing improvements in pancreatic function and other key metrics for patients with Wolfram syndrome treated with AMX0035.

Amylyx Pharmaceuticals announced its second quarter 2024 financial results, highlighted by the acquisition of avexitide and progress in its clinical programs.

Amylyx Pharmaceuticals has finalized the acquisition of the Avexitide asset from Eiger BioPharmaceuticals for $35.1 million, plus cure costs and assumed liabilities.

Amylyx Pharmaceuticals has agreed to purchase substantially all assets related to Eiger BioPharmaceuticals' Avexitide for $35.1 million, plus certain costs and assumed liabilities, pending bankruptcy court approval.

Amylyx Pharmaceuticals held its annual meeting on June 6, 2024, where stockholders elected directors, ratified the accounting firm, and voted on executive compensation matters.

Amylyx Pharmaceuticals reported its first quarter 2024 financial results, announced the discontinuation of RELYVRIO/ALBRIOZA, and highlighted progress in its clinical pipeline.

Amylyx Pharmaceuticals reported positive interim data from its Phase 2 HELIOS trial, showing AMX0035 improved key outcomes in adults with Wolfram syndrome.

Amylyx Pharmaceuticals will discontinue marketing RELYVRIO/ALBRIOZA following disappointing trial results, and implement a major restructuring including a 70% workforce reduction.

Amylyx Pharmaceuticals has appointed Dr. Bernhardt Zeiher to its Board of Directors, effective March 14, 2024, filling a vacancy and adding his extensive drug development expertise.

Amylyx Pharmaceuticals' Phase 3 PHOENIX trial for AMX0035 in ALS did not meet its primary endpoint, leading to a potential market withdrawal of the drug.

Amylyx Pharmaceuticals announced positive financial results for 2023, highlighted by $380.8 million in net product revenue and $49.3 million in net income, driven by the commercial launch of RELYVRIO.